ALX ONCOLOGY HOLDINGS INC - FORM S-1/A - EX-23.1 - July 13, 2020

Attached files

file filename
EX-23.2 - EX-23.2 - ALX ONCOLOGY HOLDINGS INCd913838dex232.htm
EX-10.11 - EX-10.11 - ALX ONCOLOGY HOLDINGS INCd913838dex1011.htm
EX-10.10 - EX-10.10 - ALX ONCOLOGY HOLDINGS INCd913838dex1010.htm
EX-10.9 - EX-10.9 - ALX ONCOLOGY HOLDINGS INCd913838dex109.htm
EX-10.8 - EX-10.8 - ALX ONCOLOGY HOLDINGS INCd913838dex108.htm
EX-10.7 - EX-10.7 - ALX ONCOLOGY HOLDINGS INCd913838dex107.htm
EX-10.6 - EX-10.6 - ALX ONCOLOGY HOLDINGS INCd913838dex106.htm
EX-10.5 - EX-10.5 - ALX ONCOLOGY HOLDINGS INCd913838dex105.htm
EX-10.4 - EX-10.4 - ALX ONCOLOGY HOLDINGS INCd913838dex104.htm
EX-10.3 - EX-10.3 - ALX ONCOLOGY HOLDINGS INCd913838dex103.htm
EX-10.2 - EX-10.2 - ALX ONCOLOGY HOLDINGS INCd913838dex102.htm
EX-5.1 - EX-5.1 - ALX ONCOLOGY HOLDINGS INCd913838dex51.htm
EX-3.2 - EX-3.2 - ALX ONCOLOGY HOLDINGS INCd913838dex32.htm
EX-3.1 - EX-3.1 - ALX ONCOLOGY HOLDINGS INCd913838dex31.htm
EX-1.1 - EX-1.1 - ALX ONCOLOGY HOLDINGS INCd913838dex11.htm
S-1/A - AMENDMENT NO. 1 TO FORM S-1 - ALX ONCOLOGY HOLDINGS INCd913838ds1a.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

ALX Oncology Holdings Inc.:

We consent to the use of our report dated June 12, 2020, except for the retroactive effect of the reverse stock split as described under the heading ‘Reverse Stock Split’ in Note 4, which is as of July 13, 2020, with respect to the balance sheet of ALX Oncology Holdings Inc. as of April 1, 2020 (inception), and the related notes, included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

San Francisco, California

July 13, 2020

ALX ONCOLOGY HOLDINGS INC Reports